Pieris Pharmaceuticals, Inc. (PIRS)
收市後：
| 前收市價 | 11.60 |
| 開市 | 11.50 |
| 買盤 | 11.53 x 100 |
| 賣出價 | 11.94 x 100 |
| 今日波幅 | 11.50 - 11.93 |
| 52 週波幅 | 10.88 - 80.80 |
| 成交量 | |
| 平均成交量 | 11,282 |
| 市值 | 14.494M |
| Beta 值 (5 年，每月) | 0.50 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -21.60 |
| 業績公佈日 | 2024年5月08日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
BenzingaWhy Pieris Pharmaceuticals Shares Shooting Higher Today?
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory franchise, including AstraZeneca Plc's (NASDAQ: AZN) discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the company of its decision to terminate the parties' R&D collaboration agreement, hand back elarekibep, and discontinue the remaining discove
InvestorPlace3 Doomed Biotech Stocks Destined for Disaster
The world of biotech stocks is notoriously difficult to predict. History is littered with companies that appeared destined for superstar status only to crash and burn. A brutal FDA approval process is partly responsible for that truth. 90% of clinical drug development leads to failure. Developmental costs are another important factor. High failure combined with high costs produces disaster in many cases. It is not uncommon for hundreds of millions of dollars to be spent, and to never produce any
Insider MonkeyPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript May 10, 2023 Operator: Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host Tom Bures, CFO. Sir, the floor is […]
